Tibet Weixinkang pharmaceutical announced that its wholly-owned subsidiary, Yangpu Jingtai Pharmaceutical Co., Ltd., has received the Calcium Gluconate Injection "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, and the pharmaceutical has passed the evaluation of generic drug quality and efficacy consistency.
卫信康：子公司洋浦京泰葡萄糖酸钙注射液通过仿制药一致性评价
Tibet Weixinkang Pharmaceutical: Subsidiary Yangpu Jingtai Calcium Gluconate Injection has passed the consistency evaluation for generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated